| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:PLK3_PLK3 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: PLK3_PLK3 | KinaseFusionDB ID: KFG4750 | FusionGDB2.0 ID: KFG4750 | Hgene | Tgene | Gene symbol | PLK3 | PLK3 | Gene ID | 1263 | 1263 | |
| Gene name | polo like kinase 3 | polo like kinase 3 | ||||||||||
| Synonyms | CNK|FNK|PLK-3|PRK | CNK|FNK|PLK-3|PRK | ||||||||||
| Cytomap | 1p34.1 | 1p34.1 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | serine/threonine-protein kinase PLK3FGF-inducible kinasecytokine-inducible serine/threonine-protein kinaseproliferation-related kinase | serine/threonine-protein kinase PLK3FGF-inducible kinasecytokine-inducible serine/threonine-protein kinaseproliferation-related kinase | ||||||||||
| Modification date | 20240305 | 20240305 | ||||||||||
| UniProtAcc | Q9H4B4 | Q9H4B4 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000465443, ENST00000372201, | ENST00000372201, ENST00000465443, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: PLK3 [Title/Abstract] AND PLK3 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | PLK3(45271046)-PLK3(45268728), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | PLK3 | GO:0000122 | negative regulation of transcription by RNA polymerase II | 19490146 |
| Hgene | PLK3 | GO:0000302 | response to reactive oxygen species | 11447225 |
| Hgene | PLK3 | GO:0006970 | response to osmotic stress | 21098032 |
| Hgene | PLK3 | GO:0006974 | DNA damage response | 19490146 |
| Hgene | PLK3 | GO:0009314 | response to radiation | 21376736 |
| Hgene | PLK3 | GO:0043066 | negative regulation of apoptotic process | 19490146 |
| Hgene | PLK3 | GO:0051302 | regulation of cell division | 20951827 |
| Hgene | PLK3 | GO:0090166 | Golgi disassembly | 14980500|19103756 |
| Hgene | PLK3 | GO:1904716 | positive regulation of chaperone-mediated autophagy | 27344333 |
| Hgene | PLK3 | GO:2000777 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxia | 20889502 |
| Tgene | PLK3 | GO:0000122 | negative regulation of transcription by RNA polymerase II | 19490146 |
| Tgene | PLK3 | GO:0000302 | response to reactive oxygen species | 11447225 |
| Tgene | PLK3 | GO:0006970 | response to osmotic stress | 21098032 |
| Tgene | PLK3 | GO:0006974 | DNA damage response | 19490146 |
| Tgene | PLK3 | GO:0009314 | response to radiation | 21376736 |
| Tgene | PLK3 | GO:0043066 | negative regulation of apoptotic process | 19490146 |
| Tgene | PLK3 | GO:0051302 | regulation of cell division | 20951827 |
| Tgene | PLK3 | GO:0090166 | Golgi disassembly | 14980500|19103756 |
| Tgene | PLK3 | GO:1904716 | positive regulation of chaperone-mediated autophagy | 27344333 |
| Tgene | PLK3 | GO:2000777 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxia | 20889502 |
| Kinase Fusion gene breakpoints across PLK3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across PLK3 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChiTaRS5.0 | BQ300580 | PLK3 | chr1 | 45271046 | PLK3 | chr1 | 45268728 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:45271046/:45268728) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PLK3 | PLK3 |
| FUNCTION: Serine/threonine-protein kinase involved in cell cycle regulation, response to stress and Golgi disassembly. Polo-like kinases act by binding and phosphorylating proteins that are already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates ATF2, BCL2L1, CDC25A, CDC25C, CHEK2, HIF1A, JUN, p53/TP53, p73/TP73, PTEN, TOP2A and VRK1. Involved in cell cycle regulation: required for entry into S phase and cytokinesis. Phosphorylates BCL2L1, leading to regulate the G2 checkpoint and progression to cytokinesis during mitosis. Plays a key role in response to stress: rapidly activated upon stress stimulation, such as ionizing radiation, reactive oxygen species (ROS), hyperosmotic stress, UV irradiation and hypoxia. Involved in DNA damage response and G1/S transition checkpoint by phosphorylating CDC25A, p53/TP53 and p73/TP73. Phosphorylates p53/TP53 in response to reactive oxygen species (ROS), thereby promoting p53/TP53-mediated apoptosis. Phosphorylates CHEK2 in response to DNA damage, promoting the G2/M transition checkpoint. Phosphorylates the transcription factor p73/TP73 in response to DNA damage, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates HIF1A and JUN is response to hypoxia. Phosphorylates ATF2 following hyperosmotic stress in corneal epithelium. Also involved in Golgi disassembly during the cell cycle: part of a MEK1/MAP2K1-dependent pathway that induces Golgi fragmentation during mitosis by mediating phosphorylation of VRK1. May participate in endomitotic cell cycle, a form of mitosis in which both karyokinesis and cytokinesis are interrupted and is a hallmark of megakaryocyte differentiation, via its interaction with CIB1. {ECO:0000269|PubMed:10557092, ECO:0000269|PubMed:11156373, ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930, ECO:0000269|PubMed:11971976, ECO:0000269|PubMed:12242661, ECO:0000269|PubMed:14968113, ECO:0000269|PubMed:14980500, ECO:0000269|PubMed:15021912, ECO:0000269|PubMed:16478733, ECO:0000269|PubMed:16481012, ECO:0000269|PubMed:17264206, ECO:0000269|PubMed:17804415, ECO:0000269|PubMed:18062778, ECO:0000269|PubMed:18650425, ECO:0000269|PubMed:19103756, ECO:0000269|PubMed:19490146, ECO:0000269|PubMed:20889502, ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:20951827, ECO:0000269|PubMed:21098032, ECO:0000269|PubMed:21264284, ECO:0000269|PubMed:21376736, ECO:0000269|PubMed:21840391, ECO:0000269|PubMed:9353331}. | FUNCTION: Serine/threonine-protein kinase involved in cell cycle regulation, response to stress and Golgi disassembly. Polo-like kinases act by binding and phosphorylating proteins that are already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates ATF2, BCL2L1, CDC25A, CDC25C, CHEK2, HIF1A, JUN, p53/TP53, p73/TP73, PTEN, TOP2A and VRK1. Involved in cell cycle regulation: required for entry into S phase and cytokinesis. Phosphorylates BCL2L1, leading to regulate the G2 checkpoint and progression to cytokinesis during mitosis. Plays a key role in response to stress: rapidly activated upon stress stimulation, such as ionizing radiation, reactive oxygen species (ROS), hyperosmotic stress, UV irradiation and hypoxia. Involved in DNA damage response and G1/S transition checkpoint by phosphorylating CDC25A, p53/TP53 and p73/TP73. Phosphorylates p53/TP53 in response to reactive oxygen species (ROS), thereby promoting p53/TP53-mediated apoptosis. Phosphorylates CHEK2 in response to DNA damage, promoting the G2/M transition checkpoint. Phosphorylates the transcription factor p73/TP73 in response to DNA damage, leading to inhibit p73/TP73-mediated transcriptional activation and pro-apoptotic functions. Phosphorylates HIF1A and JUN is response to hypoxia. Phosphorylates ATF2 following hyperosmotic stress in corneal epithelium. Also involved in Golgi disassembly during the cell cycle: part of a MEK1/MAP2K1-dependent pathway that induces Golgi fragmentation during mitosis by mediating phosphorylation of VRK1. May participate in endomitotic cell cycle, a form of mitosis in which both karyokinesis and cytokinesis are interrupted and is a hallmark of megakaryocyte differentiation, via its interaction with CIB1. {ECO:0000269|PubMed:10557092, ECO:0000269|PubMed:11156373, ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930, ECO:0000269|PubMed:11971976, ECO:0000269|PubMed:12242661, ECO:0000269|PubMed:14968113, ECO:0000269|PubMed:14980500, ECO:0000269|PubMed:15021912, ECO:0000269|PubMed:16478733, ECO:0000269|PubMed:16481012, ECO:0000269|PubMed:17264206, ECO:0000269|PubMed:17804415, ECO:0000269|PubMed:18062778, ECO:0000269|PubMed:18650425, ECO:0000269|PubMed:19103756, ECO:0000269|PubMed:19490146, ECO:0000269|PubMed:20889502, ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:20951827, ECO:0000269|PubMed:21098032, ECO:0000269|PubMed:21264284, ECO:0000269|PubMed:21376736, ECO:0000269|PubMed:21840391, ECO:0000269|PubMed:9353331}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of PLK3_PLK3 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| PLK3 | Q9H4B4 | human | ATF2 | P15336 | T69 | sVIVADQtPtPtRFL | |
| PLK3 | Q9H4B4 | human | YWHAE | P62258 | T208 | DAIAELDtLsEEsyk | 14-3-3 |
| PLK3 | Q9H4B4 | human | ATF2 | P15336 | T71 | IVADQtPtPtRFLkN | |
| PLK3 | Q9H4B4 | human | TOP2A | P11388 | T1343 | FsDFDEKtDDEDFVP | |
| PLK3 | Q9H4B4 | human | CALU | O43852 | S44 | kVHNDAQsFDyDHDA | |
| PLK3 | Q9H4B4 | human | CHEK2 | O96017 | S62 | sSSGTLSsLEtVstQ | |
| PLK3 | Q9H4B4 | human | HSP90AB1 | P08238 | S718 | LEGDEDAsRMEEVD_ | |
| PLK3 | Q9H4B4 | human | CALU | O43852 | T254 | GkMDKEEtkDWILPs | |
| PLK3 | Q9H4B4 | human | CALU | O43852 | T60 | LGAEEAktFDQLtPE | |
| PLK3 | Q9H4B4 | human | PTEN | P60484 | S370 | TSVtPDVsDNEPDHy | |
| PLK3 | Q9H4B4 | human | CDC25C | P30307 | S191 | EDQAEEIsDELMEFs | M-inducer_phosp |
| PLK3 | Q9H4B4 | human | SNCB | Q16143 | S118 | LMEPEGEsYEDPPQE | Synuclein |
| PLK3 | Q9H4B4 | human | BCL2L1 | Q07817 | S49 | ESEMEtPsAINGNPS | |
| PLK3 | Q9H4B4 | human | SNCA | P37840 | S129 | NEAyEMPsEEGyQDy | Synuclein |
| PLK3 | Q9H4B4 | human | HIF1A | Q16665 | S657 | EttsATssPYRDTQS | |
| PLK3 | Q9H4B4 | human | CHEK2 | O96017 | S73 | VstQELYsIPEDQEP | |
| PLK3 | Q9H4B4 | human | PTEN | P60484 | T366 | ASSsTSVtPDVsDNE | |
| PLK3 | Q9H4B4 | human | CALU | O43852 | T196 | KDIVVQEtMEDIDKN | EF-hand_5 |
| PLK3 | Q9H4B4 | human | NPM1 | P06748 | S4 | ____MEDsMDMDMsP | |
| PLK3 | Q9H4B4 | human | CDC25C | P30307 | S198 | sDELMEFsLKDQEAK | M-inducer_phosp |
| PLK3 | Q9H4B4 | human | JUN | P05412 | S73 | VGLLkLAsPELERLI | Jun |
| PLK3 | Q9H4B4 | human | TP53 | P04637 | S20 | PLsQEtFsDLWkLLP | P53_TAD |
| PLK3 | Q9H4B4 | human | CCNB1 | P14635 | S133 | sPsPMETsGCAPAEE | |
| PLK3 | Q9H4B4 | human | JUN | P05412 | S63 | kNsDLLtsPDVGLLk | Jun |
| PLK3 | Q9H4B4 | human | CASP8 | Q14790 | T273 | DAGALTTtFEELHFE | Peptidase_C14 |
| PLK3 | Q9H4B4 | human | VRK1 | Q99986 | S342 | DDGkLDLsVVENGGL | |
| PLK3 | Q9H4B4 | human | CDC25A | P30304 | T80 | RMGssEstDsGFCLD | |
| PLK3 | Q9H4B4 | human | OCLN | Q16625 | S471 | LDDyREEsEEyMAAA | Occludin_ELL |
| PLK3 | Q9H4B4 | human | HIF1A | Q16665 | S576 | DDDFQLRsFDQLSPL | HIF-1 |
| PLK3 | Q9H4B4 | human | CALU | O43852 | T177 | IATkEEFtAFLHPEE |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| PLK3 | ID | Description | 0.00e+00 |
| PLK3 | GO:0051402 | neuron apoptotic process | 5.63e-06 |
| PLK3 | GO:0044839 | cell cycle G2/M phase transition | 5.63e-06 |
| PLK3 | GO:1901987 | regulation of cell cycle phase transition | 5.63e-06 |
| PLK3 | GO:1904029 | regulation of cyclin-dependent protein kinase activity | 7.35e-06 |
| PLK3 | GO:1902751 | positive regulation of cell cycle G2/M phase transition | 7.35e-06 |
| PLK3 | GO:0071214 | cellular response to abiotic stimulus | 7.35e-06 |
| PLK3 | GO:0104004 | cellular response to environmental stimulus | 7.35e-06 |
| PLK3 | GO:0043523 | regulation of neuron apoptotic process | 2.04e-05 |
| PLK3 | GO:1902749 | regulation of cell cycle G2/M phase transition | 2.04e-05 |
| PLK3 | GO:1901522 | positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 1.04e-04 |
| PLK3 | GO:0010948 | negative regulation of cell cycle process | 1.04e-04 |
| PLK3 | GO:0031647 | regulation of protein stability | 1.04e-04 |
| PLK3 | GO:0071478 | cellular response to radiation | 1.29e-04 |
| PLK3 | GO:0070242 | thymocyte apoptotic process | 1.30e-04 |
| PLK3 | GO:1901990 | regulation of mitotic cell cycle phase transition | 1.39e-04 |
| PLK3 | GO:0010639 | negative regulation of organelle organization | 1.42e-04 |
| PLK3 | GO:0000079 | regulation of cyclin-dependent protein serine/threonine kinase activity | 1.42e-04 |
| PLK3 | GO:0045936 | negative regulation of phosphate metabolic process | 1.56e-04 |
| PLK3 | GO:0010563 | negative regulation of phosphorus metabolic process | 1.56e-04 |
| PLK3 | GO:0097194 | execution phase of apoptosis | 1.67e-04 |
| PLK3 | GO:0001701 | in utero embryonic development | 1.77e-04 |
| PLK3 | GO:0050821 | protein stabilization | 1.86e-04 |
| PLK3 | GO:0045786 | negative regulation of cell cycle | 1.93e-04 |
| PLK3 | GO:0071480 | cellular response to gamma radiation | 1.93e-04 |
| PLK3 | GO:0010971 | positive regulation of G2/M transition of mitotic cell cycle | 2.31e-04 |
| PLK3 | GO:0009314 | response to radiation | 2.37e-04 |
| PLK3 | GO:0045930 | negative regulation of mitotic cell cycle | 2.91e-04 |
| PLK3 | GO:0043618 | regulation of transcription from RNA polymerase II promoter in response to stress | 3.08e-04 |
| PLK3 | GO:0034599 | cellular response to oxidative stress | 3.10e-04 |
| PLK3 | GO:0044772 | mitotic cell cycle phase transition | 3.35e-04 |
| PLK3 | GO:1901989 | positive regulation of cell cycle phase transition | 3.35e-04 |
| PLK3 | GO:0007006 | mitochondrial membrane organization | 3.35e-04 |
| PLK3 | GO:1903829 | positive regulation of protein localization | 3.35e-04 |
| PLK3 | GO:0071887 | leukocyte apoptotic process | 3.35e-04 |
| PLK3 | GO:1901988 | negative regulation of cell cycle phase transition | 3.85e-04 |
| PLK3 | GO:0043620 | regulation of DNA-templated transcription in response to stress | 3.99e-04 |
| PLK3 | GO:0071900 | regulation of protein serine/threonine kinase activity | 4.18e-04 |
| PLK3 | GO:0071634 | regulation of transforming growth factor beta production | 4.74e-04 |
| PLK3 | GO:0043467 | regulation of generation of precursor metabolites and energy | 5.06e-04 |
| PLK3 | GO:0000086 | G2/M transition of mitotic cell cycle | 5.07e-04 |
| PLK3 | GO:0007093 | mitotic cell cycle checkpoint signaling | 5.23e-04 |
| PLK3 | GO:0071604 | transforming growth factor beta production | 5.29e-04 |
| PLK3 | GO:0062197 | cellular response to chemical stress | 6.01e-04 |
| PLK3 | GO:0097193 | intrinsic apoptotic signaling pathway | 6.05e-04 |
| PLK3 | GO:0010332 | response to gamma radiation | 7.22e-04 |
| PLK3 | GO:1902895 | positive regulation of miRNA transcription | 7.49e-04 |
| PLK3 | GO:0043524 | negative regulation of neuron apoptotic process | 7.86e-04 |
| PLK3 | GO:0070231 | T cell apoptotic process | 9.98e-04 |
| PLK3 | GO:0046902 | regulation of mitochondrial membrane permeability | 1.14e-03 |
Top |
Related Drugs to PLK3_PLK3 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning PLK3-PLK3 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to PLK3_PLK3 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |